WilmerHale Advises Argos Therapeutics in Pricing of $50M Public Offering

Download IconDownload Print IconPrint

WilmerHale Advises Argos Therapeutics in Pricing of $50M Public Offering

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Argos Therapeutics, Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, announced the pricing of its public offering of $50 million. 

The WilmerHale team was led by Partner Stuart Falber and included Associate Leora Rodenstein, Senior Associate Ryan Mitteness, Associate Andrea Sorrentino, Attorney Heidi Treiber and Senior Associate Mia Kelley. Partner Julie Hogan Rodgers and Associate Leah Segal (Tax) were also involved.

Read Argos Therapeutics' press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel